Response to Omalizumab as an Add-On Therapy in the Treatment of Allergic Asthma in Adult Chinese Patients—A Retrospective Study

(a) Background: Omalizumab is an anti-IgE humanized monoclonal antibody marketed in China for the conventional treatment of poorly controlled moderate-to-severe allergic asthma. Numerous clinical trials have demonstrated the effectiveness of omalizumab, but the data from studies in actual clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Cao, Linfeng, Zhang, Ming, Fei, Chunyuan, Deng, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787189/
https://www.ncbi.nlm.nih.gov/pubmed/36560478
http://dx.doi.org/10.3390/vaccines10122068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787189/
https://www.ncbi.nlm.nih.gov/pubmed/36560478
http://dx.doi.org/10.3390/vaccines10122068

Ejemplares similares